News

Prothena and Celgene are teaming up to develop treatments for a range of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The collaboration will focus on therapies that can target proteins such as tau and TDP-43 that scientists have linked to these disorders. “The programs we have chosen to collaborate…

Patients with amyotrophic lateral sclerosis (ALS) show higher rates of sleep apnea that is often accompanied by nocturnal hypoventilation, according to a retrospective study. Researchers also found that a method called transcutaneous capnography is able to reliably detect nocturnal hypoventilation, or insufficient breathing, in ALS patients. The…

Difficulty sharing vast amounts of information — the so-called big data — can slow the pace of scientific advancement, experts say. A University of Washington team has come up with a way to help neuroscience researchers share huge swaths of MRI information about ALS and similar disorders. The information deals…

Three organizations that are fighting neurodegenerative disorders have teamed up to challenge researchers around the world to come up with new treatment approaches. The ALS Association, the Huntington’s Disease Society of America (HDSA) and Teva Pharmaceuticals have started the crowdsourcing effort, known as the Teva CNS Target Identification…

Scientists have discovered a key role for the ALS-linked protein known as fused in sarcoma (FUS) in a system that is crucial to regulating gene expression. The study, “FUS Regulates Activity of MicroRNA-Mediated Gene Silencing,” was published in the journal Molecular Cell. FUS is a DNA/RNA-binding protein involved in repairing…

Syracuse University researchers have obtained further insight into the protein UBQLN2, whose mutations have been associated with the development of amyotrophic lateral sclerosis (ALS). The study, “Ubiquitin Modulates Liquid-Liquid Phase Separation of UBQLN2 via Disruption of Multivalent Interactions,” was published in the journal Molecular Cell. There are many…